{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-127056","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.116912+00:00","generated_at":"2026-05-30T00:30:03.064317+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alector secures up to $50M credit facility from Hercules Capital; draws $10M initially","bullets":["Initial $10M drawn at closing; $15M available upon request through June 2026; $25M at lender's discretion.","Interest rate at prime plus 1.05% or 8.05% (greater); maturity December 1, 2028.","Cash and investments $457.2M as of Sept 30, 2024; company believes existing cash funds operations through 2026.","CFO cites transformational data from AL002 Phase 2 and latozinemab Phase 3 trials within current runway.","Facility is secured by substantially all assets, with exceptions for certain existing agreements."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-127056","json":"https://secwatch.observer/filing/0000950170-24-127056.json","markdown":"https://secwatch.observer/filing/0000950170-24-127056.md","text":"https://secwatch.observer/filing/0000950170-24-127056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017024127056/0000950170-24-127056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017024127056/alec-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:30:03.064317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}